Double‐blind, placebo‐controlled study of lurasidone monotherapy for the treatment of bipolar I depression

AIM: Previous studies conducted primarily in the USA and Europe have demonstrated the efficacy and safety of lurasidone 20–120 mg/day for the treatment of bipolar I depression. The aim of the current study was to evaluate the efficacy and safety of lurasidone monotherapy for the treatment of bipolar...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Tadafumi, Ishigooka, Jun, Miyajima, Mari, Watabe, Kei, Fujimori, Tomohiro, Masuda, Takahiro, Higuchi, Teruhiko, Vieta, Eduard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756283/
https://www.ncbi.nlm.nih.gov/pubmed/32827348
http://dx.doi.org/10.1111/pcn.13137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756283/
https://www.ncbi.nlm.nih.gov/pubmed/32827348
http://dx.doi.org/10.1111/pcn.13137

Ejemplares similares